GlobalData
http://www.globaldata.com/reportstore/
記事の詳細を見てみると、また色々と新しい動向が明らかになってきたようです！
ちょっとその一部をまとめてみると…、
- 2010年の単純ヘルペス市場は約2,350万ドルで、2005年に評価されていた市場価値（2,513万ドル）からは少し減少している。ただ、同市場には今後様々な新薬が導入されると予想されており、その結果、同市場規模は2018年には3,947万ドルに上昇する見込みである。
- 現段階で主力となっている治療薬は、Zovirax (200mg and 400mg), Famvir、ValtrexなどのDNAポリメラーゼ阻害薬（DNAの複製時に必要となるポリメラーゼという酵素を阻害する薬？）、DenavirとAbrevaのような軟膏でいわゆる「一時しのぎ」的な薬だが…、
- Zovirax、Famvir、Valtrexは特許がすでに切れており、DenavirとAbrevaに関しては、それぞれ2014年と2015年に特許が切れる予定になっている。
- ここ最近の動向をみると、
NanoBioがGlaxoSmithKlineとのパートナーシップの下に開発を進めているNB001が2014年にも市場に投入される可能性がある
GlaxoSmithKlineとのパートナーシップの下に開発を進めているもう一つのバイオ系会社（BioAlliance）が治験を進めているBA021が2013年にも実用化される見込みである
といった好材料が多く、経済市場としても非常に期待できるようです。
GlobalDataの調査によると、現在のところ「27の新薬」が開発途中にあるようで、そのうちの20が何かしらの治験（Phase I、II、III）段階にあるようです。もっとも進んでいるPhase IIIにある新薬が、先に取り上げた、NB001とBA021（双方共に抗HSV1薬剤）で、Phase II段階にあるのは6種類、Phase I段階にあるのが5種類ほどあるようです…（ちょっと数が合わない気もしますが…？）
これらの中でも注目株は、
- NB-001（NanoBio+GlaxoSmithKline）
- BA021（BioAlliance+GlaxoSmithKline）
- AIC316（AiCuris）
- RPI-78M（Nutra Pharma Corporation）
のようで、これらの新薬開発が市場の拡大に大きく貢献しているようです！
着々と新薬の開発も進んでいるようですね！
今後に期待です！
Herpes Simplex Therapeutics - Pipeline Assessment and Market Forecasts to 2018
The Herpes Simplex Therapeutics Market is Forecast to Show significant Growth until 2018
http://www.prlog.org/11660978-herpes-simplex-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html
FOR IMMEDIATE RELEASE
PRLog (Press Release) - Sep 15, 2011 - The global herpes simplex therapeutics market was worth approximately $2,350.1m in 2010. In 2005 the market was valued at $2,513.8m and declined at a compound annual growth rate (CAGR) of 1.3% from 2005 to 2010. The global herpes simplex therapeutics market is expected to reach $3,947.4m by 2018, after growing at a CAGR of 6.7% from 2010. The primary factor contributing to the increase in revenues over the forecast period is the expected launch of pipeline products. Presently, the therapeutic regimen for herpes simplex is dominated by a range of DNA polymerase inhibitors, which include Zovirax (200mg and 400mg), Famvir, Valtrex, Denavir and OTC (Over-the-Counter) products such as Abreva. Of these approved therapies Zovirax, Famvir and Valtrex have gone off patent. Topical therapies such as Abreva and Denavir will lose their patents in 2014 and 2015, respectively. The herpes simplex therapeutics market is a significantly genericized market, with many brands across the seven geographies (the US, France, Germany, Italy, Spain, the UK and Japan). The herpes simplex pipeline is dominated by first in class molecules. In the late stages of the pipeline, NB-001 is a novel topical treatment for oral herpes. It is being developed by NanoBio and is expected to launch in 2014. BA-021 another molecule in Phase III is being developed by BioAlliance in partnership with GlaxoSmithKline (GSK). BA021 is expected to launch in the market in 2013. In addition to these drugs, the pipeline consists of many novel therapies that will drive market growth in the future. This is dependent on whether they are able to produce satisfactory results and pass through the regulatory hurdles.
Global Data's pipeline analysis revealed that there are 27 candidates in the various stages of clinical development. There are 20 first in class molecules across all the phases of development. The Phase III stage of development consists of two molecules. These are NB-001 and BA021. Of these, NB-001 is first in class, whereas BA021 is a product extension. Phase II has six pipeline molecules. There are five molecules in Phase I. The preclinical and discovery stage combined consist of fourteen molecules. NB- 001, BA021, AIC316 and RPI-78M are among the promising drugs under clinical development. NB-001 is a novel drug under Phase III development by NanoBio in partnership with GSK. In Phase II trial results, NB-001 has shown significant antimicrobial activity against the HSV that causes herpes labialis. BA021 (acyclovir lauriad) is being developed by BioAlliance and is based on mucoadhesive oral tablet technology. AIC316 is being developed by AiCuris. The company has completed Phase II trials two months earlier than the expected trial completion time and is seeking partners for the further development of the drug. RPI-78M is a novel antiviral drug being developed by Nutra Pharma Corporation. NB-001 and BA021 are expected to be launched in the market during the late forecast period and will contribute to the growth in the market.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages ...
The herpes simplex therapeutics market has significant unmet need. The currently marketed antivirals are efficacious in treating herpes simplex symptomatically by healing the lesion faster. However, significant unmet need lies in the therapeutic market as the approved antivirals in the market are only able to reduce the frequency of herpes simplex reoccurrence to a certain extent. These drugs also require frequent dosing, which leads to a reduction in patient compliance. A significant unmet need also lies within the prophylactic market of herpes simplex.
GlobalData, the industry analysis specialist, has released its new report, “Herpes Simplex Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global alopecia market. The report identifies the key trends shaping and driving the global alopecia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global alopecia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Her ...
Visit our report store:
http://www.globaldata.com/reportstore
0 件のコメント:
コメントを投稿